

# Aarskog-Scott Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/A9A1C58FCFABEN.html>

Date: May 2024

Pages: 139

Price: US\$ 6,499.00 (Single User License)

ID: A9A1C58FCFABEN

## Abstracts

The 7 major aarskog-scott syndrome markets reached a value of US\$ 2.2 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US\$ 3.8 Billion by 2034, exhibiting a growth rate (CAGR) of 4.99% during 2024-2034.

The Aarskog-Scott syndrome market has been comprehensively analyzed in IMARC's new report titled "Aarskog-Scott Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Aarskog-Scott syndrome, also known as faciogenital dysplasia, refers to a rare genetic disorder that affects various parts of the body. It is characterized by a distinct pattern of facial and skeletal abnormalities, as well as certain developmental and growth delays. The syndrome primarily affects males, although milder cases can also occur in females. Individuals suffering from this ailment often have widely spaced eyes, a short nose with a broad nasal bridge, droopy eyelids, an underdeveloped midface, epicanthal folds, and a flat philtrum. Various other indications associated with the illness include small stature, abnormal curvature of the spine, big toes and thumbs, a deformed scrotum, a sunken chest, speech and language delays, learning difficulties, behavioral issues, hyperactivity, impulsivity, etc. The diagnosis of Aarskog-Scott syndrome typically involves a combination of clinical evaluation, medical history review, and physical examination. The healthcare provider might also recommend genetic testing to identify mutations or alterations in the gene that are responsible for the underlying condition. Several radiological studies, like X-rays of the hands and feet, are further conducted to assess skeletal and soft tissue abnormalities associated with the disorder.

The increasing cases of genetic mutations that can disrupt the proper signaling and communication within cells and tissues are primarily driving the Aarskog-Scott

syndrome market. In addition to this, the inflating utilization of growth hormone therapy, which can promote linear development in individuals suffering from the illness, is also creating a positive outlook for the market. Moreover, the escalating application of cleft lip or palate surgery, owing to its numerous advantages, such as decreased structural abnormality, improved self-esteem and social interactions, enhanced facial aesthetics, etc., is further bolstering the market growth. Apart from this, the widespread adoption of physical and speech therapies, since they aim to boost functional abilities, mobility, communication skills, and overall quality of life in patients while reducing the risk of falls, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of gene therapy that targets to correct or replace the faulty gene, leading to the production of operational proteins and potentially alleviating the symptoms of the condition, is expected to drive the Aarskog-Scott syndrome market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the Aarskog-Scott syndrome market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for Aarskog-Scott syndrome and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Aarskog-Scott syndrome market in any manner.

#### Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

#### Countries Covered

United States

Germany

France

United Kingdom  
Italy  
Spain  
Japan

### Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario  
Historical, current, and future performance of the Aarskog-Scott syndrome market  
Historical, current, and future performance of various therapeutic categories in the market

Sales of various drugs across the Aarskog-Scott syndrome market

Reimbursement scenario in the market

In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current Aarskog-Scott syndrome marketed drugs and late-stage pipeline drugs.

### In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

### Late-Stage Pipeline Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

Key Questions Answered in this Report:

Market Insights

How has the Aarskog-Scott syndrome market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they

expected to perform till 2034?

What was the country-wise size of the Aarskog-Scott syndrome market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the Aarskog-Scott syndrome market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

## Epidemiology Insights

What is the number of prevalent cases (2018-2034) of Aarskog-Scott syndrome across the seven major markets?

What is the number of prevalent cases (2018-2034) of Aarskog-Scott syndrome by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of Aarskog-Scott syndrome by gender across the seven major markets?

How many patients are diagnosed (2018-2034) with Aarskog-Scott syndrome across the seven major markets?

What is the size of the Aarskog-Scott syndrome patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of Aarskog-Scott syndrome?

What will be the growth rate of patients across the seven major markets?

## Aarskog-Scott Syndrome: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for Aarskog-Scott syndrome drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Aarskog-Scott syndrome market?

What are the key regulatory events related to the Aarskog-Scott syndrome market?

What is the structure of clinical trial landscape by status related to the Aarskog-Scott

syndrome market?

What is the structure of clinical trial landscape by phase related to the Aarskog-Scott syndrome market?

What is the structure of clinical trial landscape by route of administration related to the Aarskog-Scott syndrome market?

## Contents

### **1 PREFACE**

### **2 SCOPE AND METHODOLOGY**

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
  - 2.3.1 Primary Sources
  - 2.3.2 Secondary Sources
- 2.4 Market Estimation
  - 2.4.1 Bottom-Up Approach
  - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

### **3 EXECUTIVE SUMMARY**

### **4 AARSKOG-SCOTT SYNDROME - INTRODUCTION**

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

### **5 AARSKOG-SCOTT SYNDROME - DISEASE OVERVIEW**

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

### **6 PATIENT JOURNEY**

### **7 AARSKOG-SCOTT SYNDROME - EPIDEMIOLOGY AND PATIENT POPULATION**

- 7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
  - 7.2.1 Epidemiology Scenario (2018-2023)
  - 7.2.2 Epidemiology Forecast (2024-2034)
  - 7.2.3 Epidemiology by Age (2018-2034)
  - 7.2.4 Epidemiology by Gender (2018-2034)
  - 7.2.5 Diagnosed Cases (2018-2034)
  - 7.2.6 Patient Pool/Treated Cases (2018-2034)
- 7.3 Epidemiology Scenario - United States
  - 7.3.1 Epidemiology Scenario (2018-2023)
  - 7.3.2 Epidemiology Forecast (2024-2034)
  - 7.3.3 Epidemiology by Age (2018-2034)
  - 7.3.4 Epidemiology by Gender (2018-2034)
  - 7.3.5 Diagnosed Cases (2018-2034)
  - 7.3.6 Patient Pool/Treated Cases (2018-2034)
- 7.4 Epidemiology Scenario - Germany
  - 7.4.1 Epidemiology Scenario (2018-2023)
  - 7.4.2 Epidemiology Forecast (2024-2034)
  - 7.4.3 Epidemiology by Age (2018-2034)
  - 7.4.4 Epidemiology by Gender (2018-2034)
  - 7.4.5 Diagnosed Cases (2018-2034)
  - 7.4.6 Patient Pool/Treated Cases (2018-2034)
- 7.5 Epidemiology Scenario - France
  - 7.5.1 Epidemiology Scenario (2018-2023)
  - 7.5.2 Epidemiology Forecast (2024-2034)
  - 7.5.3 Epidemiology by Age (2018-2034)
  - 7.5.4 Epidemiology by Gender (2018-2034)
  - 7.5.5 Diagnosed Cases (2018-2034)
  - 7.5.6 Patient Pool/Treated Cases (2018-2034)
- 7.6 Epidemiology Scenario - United Kingdom
  - 7.6.1 Epidemiology Scenario (2018-2023)
  - 7.6.2 Epidemiology Forecast (2024-2034)
  - 7.6.3 Epidemiology by Age (2018-2034)
  - 7.6.4 Epidemiology by Gender (2018-2034)
  - 7.6.5 Diagnosed Cases (2018-2034)
  - 7.6.6 Patient Pool/Treated Cases (2018-2034)
- 7.7 Epidemiology Scenario - Italy
  - 7.7.1 Epidemiology Scenario (2018-2023)
  - 7.7.2 Epidemiology Forecast (2024-2034)
  - 7.7.3 Epidemiology by Age (2018-2034)

- 7.7.4 Epidemiology by Gender (2018-2034)
- 7.7.5 Diagnosed Cases (2018-2034)
- 7.7.6 Patient Pool/Treated Cases (2018-2034)
- 7.8 Epidemiology Scenario - Spain
  - 7.8.1 Epidemiology Scenario (2018-2023)
  - 7.8.2 Epidemiology Forecast (2024-2034)
  - 7.8.3 Epidemiology by Age (2018-2034)
  - 7.8.4 Epidemiology by Gender (2018-2034)
  - 7.8.5 Diagnosed Cases (2018-2034)
  - 7.8.6 Patient Pool/Treated Cases (2018-2034)
- 7.9 Epidemiology Scenario - Japan
  - 7.9.1 Epidemiology Scenario (2018-2023)
  - 7.9.2 Epidemiology Forecast (2024-2034)
  - 7.9.3 Epidemiology by Age (2018-2034)
  - 7.9.4 Epidemiology by Gender (2018-2034)
  - 7.9.5 Diagnosed Cases (2018-2034)
  - 7.9.6 Patient Pool/Treated Cases (2018-2034)

## **8 AARSKOG-SCOTT SYNDROME - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES**

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

## **9 AARSKOG-SCOTT SYNDROME - UNMET NEEDS**

## **10 AARSKOG-SCOTT SYNDROME - KEY ENDPOINTS OF TREATMENT**

## **11 AARSKOG-SCOTT SYNDROME - MARKETED PRODUCTS**

- 11.1 List of Aarskog-Scott Syndrome Marketed Drugs Across the Top 7 Markets
  - 11.1.1 Drug Name – Company Name
    - 11.1.1.1 Drug Overview
    - 11.1.1.2 Mechanism of Action
    - 11.1.1.3 Regulatory Status
    - 11.1.1.4 Clinical Trial Results
    - 11.1.1.5 Sales Across Major Markets

Kindly note that the complete list of marketed drugs has been provided in the report.



## **12 AARSKOG-SCOTT SYNDROME - PIPELINE DRUGS**

### 12.1 List of Aarskog-Scott Syndrome Pipeline Drugs Across the Top 7 Markets

#### 12.1.1 Drug Name – Company Name

##### 12.1.1.1 Drug Overview

##### 12.1.1.2 Mechanism of Action

##### 12.1.1.3 Clinical Trial Results

##### 12.1.1.4 Safety and Efficacy

##### 12.1.1.5 Regulatory Status

Kindly note that the complete list of pipeline drugs has been provided in the report.

## **13. AARSKOG-SCOTT SYNDROME - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS**

## **14. AARSKOG-SCOTT SYNDROME – CLINICAL TRIAL LANDSCAPE**

### 14.1 Drugs by Status

### 14.2 Drugs by Phase

### 14.3 Drugs by Route of Administration

### 14.4 Key Regulatory Events

## **15 AARSKOG-SCOTT SYNDROME - MARKET SCENARIO**

### 15.1 Market Scenario - Key Insights

### 15.2 Market Scenario - Top 7 Markets

#### 15.2.1 Aarskog-Scott Syndrome - Market Size

##### 15.2.1.1 Market Size (2018-2023)

##### 15.2.1.2 Market Forecast (2024-2034)

#### 15.2.2 Aarskog-Scott Syndrome - Market Size by Therapies

##### 15.2.2.1 Market Size by Therapies (2018-2023)

##### 15.2.2.2 Market Forecast by Therapies (2024-2034)

### 15.3 Market Scenario - United States

#### 15.3.1 Aarskog-Scott Syndrome - Market Size

##### 15.3.1.1 Market Size (2018-2023)

##### 15.3.1.2 Market Forecast (2024-2034)

#### 15.3.2 Aarskog-Scott Syndrome - Market Size by Therapies

##### 15.3.2.1 Market Size by Therapies (2018-2023)

##### 15.3.2.2 Market Forecast by Therapies (2024-2034)

#### 15.3.3 Aarskog-Scott Syndrome - Access and Reimbursement Overview

## 15.4 Market Scenario - Germany

### 15.4.1 Aarskog-Scott Syndrome - Market Size

#### 15.4.1.1 Market Size (2018-2023)

#### 15.4.1.2 Market Forecast (2024-2034)

### 15.4.2 Aarskog-Scott Syndrome - Market Size by Therapies

#### 15.4.2.1 Market Size by Therapies (2018-2023)

#### 15.4.2.2 Market Forecast by Therapies (2024-2034)

### 15.4.3 Aarskog-Scott Syndrome - Access and Reimbursement Overview

## 15.5 Market Scenario - France

### 15.5.1 Aarskog-Scott Syndrome - Market Size

#### 15.5.1.1 Market Size (2018-2023)

#### 15.5.1.2 Market Forecast (2024-2034)

### 15.5.2 Aarskog-Scott Syndrome - Market Size by Therapies

#### 15.5.2.1 Market Size by Therapies (2018-2023)

#### 15.5.2.2 Market Forecast by Therapies (2024-2034)

### 15.5.3 Aarskog-Scott Syndrome - Access and Reimbursement Overview

## 15.6 Market Scenario - United Kingdom

### 15.6.1 Aarskog-Scott Syndrome - Market Size

#### 15.6.1.1 Market Size (2018-2023)

#### 15.6.1.2 Market Forecast (2024-2034)

### 15.6.2 Aarskog-Scott Syndrome - Market Size by Therapies

#### 15.6.2.1 Market Size by Therapies (2018-2023)

#### 15.6.2.2 Market Forecast by Therapies (2024-2034)

### 15.6.3 Aarskog-Scott Syndrome - Access and Reimbursement Overview

## 15.7 Market Scenario - Italy

### 15.7.1 Aarskog-Scott Syndrome - Market Size

#### 15.7.1.1 Market Size (2018-2023)

#### 15.7.1.2 Market Forecast (2024-2034)

### 15.7.2 Aarskog-Scott Syndrome - Market Size by Therapies

#### 15.7.2.1 Market Size by Therapies (2018-2023)

#### 15.7.2.2 Market Forecast by Therapies (2024-2034)

### 15.7.3 Aarskog-Scott Syndrome - Access and Reimbursement Overview

## 15.8 Market Scenario - Spain

### 15.8.1 Aarskog-Scott Syndrome - Market Size

#### 15.8.1.1 Market Size (2018-2023)

#### 15.8.1.2 Market Forecast (2024-2034)

### 15.8.2 Aarskog-Scott Syndrome - Market Size by Therapies

#### 15.8.2.1 Market Size by Therapies (2018-2023)

#### 15.8.2.2 Market Forecast by Therapies (2024-2034)

- 15.8.3 Aarskog-Scott Syndrome - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
  - 15.9.1 Aarskog-Scott Syndrome - Market Size
    - 15.9.1.1 Market Size (2018-2023)
    - 15.9.1.2 Market Forecast (2024-2034)
  - 15.9.2 Aarskog-Scott Syndrome - Market Size by Therapies
    - 15.9.2.1 Market Size by Therapies (2018-2023)
    - 15.9.2.2 Market Forecast by Therapies (2024-2034)
  - 15.9.3 Aarskog-Scott Syndrome - Access and Reimbursement Overview

## **16 AARSKOG-SCOTT SYNDROME - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS**

## **17 AARSKOG-SCOTT SYNDROME MARKET - SWOT ANALYSIS**

- 17.1 Strengths
- 17.2 Weaknesses
- 17.3 Opportunities
- 17.4 Threats

## **18 AARSKOG-SCOTT SYNDROME MARKET – STRATEGIC RECOMMENDATIONS**

## **19 APPENDIX**

## I would like to order

Product name: Aarskog-Scott Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/A9A1C58FCFABEN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A9A1C58FCFABEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

